Global Regulatory Update

GUEST EDITOR

Dr Christiane Niederlaender, Senior Quality Assessor, Biologicals, MHRA

The past few years have witnessed an unprecedented increase in the range of expedited regulatory pathways potentially available to cell & gene therapy developers across the world. From RMAT to PRIME, and from Breakthrough Designation to the PMD Act, a weight of experience and insight now exists to help you capitalize on the benefits whilst avoiding the pitfalls.